Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2002-09-20
2008-08-05
Pak, Michael (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S139100, C424S143100, C424S141100
Reexamination Certificate
active
07407655
ABSTRACT:
The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.
REFERENCES:
patent: 5094941 (1992-03-01), Hart
patent: 5532136 (1996-07-01), Carlson et al.
patent: 5543503 (1996-08-01), Chuntharapai et al.
patent: 5545616 (1996-08-01), Woodruff
patent: 5629283 (1997-05-01), Nicola et al.
patent: 5648219 (1997-07-01), MacKay et al.
patent: 5672694 (1997-09-01), Campbell et al.
patent: 5695945 (1997-12-01), Tsuji
patent: 6140064 (2000-10-01), Loetscher et al.
patent: 6171590 (2001-01-01), Howard et al.
patent: 6184358 (2001-02-01), Loetscher et al.
patent: 2001/0006942 (2001-07-01), Howard et al.
patent: 2005/0112119 (2005-05-01), Qin et al.
patent: 4332256 (1995-03-01), None
patent: WO91/02063 (1991-02-01), None
patent: WO94/12635 (1994-06-01), None
patent: WO94/24282 (1994-10-01), None
patent: WO95/08576 (1995-03-01), None
patent: WO97/25340 (1997-07-01), None
patent: WO98/32858 (1998-07-01), None
patent: WO 01/72334 (2001-10-01), None
Strieter et al., Semin Cancer Biol. 2004, vol. 14(3): 195-200, esp. p. 197: column 2, paragraph 3.
Miller G., Science 2002, vol. 297(5584): pp. 1116-1118, esp. p. 116: column 2, lines 1-3.
Murphy, P.M., “The Molecular Biology of Leukocyte Chemoattractant Receptors,”Annu. Rev. Immunol., 12:593-633 (1994).
Marchese, A. et al., “Cloning and Chromosomal Mapping of Three Novel Genes, GPR9, GPR10, and GPR14, Encoding Receptors Related to Interleukin 8, Neuropeptide Y, and Somatostatin Receptors,”Genomics, 29:335-344 (1995).
GenBank Accession No. U32674, submitted by Marchese, A. et al., first released Oct. 2, 1995 according to personnel at the National Center for Biotechnology Information.
Taub, D.D., et al., “Recombinant Human Interferon-inducible Protein 10 is a Chemoattractant for Human Monocytes and T Lymphocytes and Promotes T Cell Adhesion to Endothelial Cells,”J. Exp. Med., 177:1809-1814 (1993).
Sarris, A.H., et al., “Human Interferon-inducible Protein 10: Expression and Purification of Recombinant Protein Demonstrate Inhibition of Early Human Hematopoietic Progenitors,”J. Exp. Med., 178:1127-1132 (1993).
Luster, A.D. and Leder, P., “IP-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-dependent Antitumor Response In Vivo,”J. Exp. Med., 178:1057-1065 (1993).
Angiolillo, A.L., et al., “Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo,”J. Exp. Med., 182:155-162 (1995).
Luster, A.D., et al., “The IP-10 Chemokine Binds to a Specific Cell Surface Heparan Sulfate Site Shared with Platelet Factor 4 and Inhibits Endothelial Cell Proliferation,”J. Exp. Med., 182:219-231 (1995).
Taub, D.D., et al., “α and β Chemokines Induce NK Cell Migration and Enhance NK-Mediated Cytolysis,”J. Immunol., 155:3877-3888 (1995).
Luster, A.D., et al., “γ-Interferon Transcriptionally Regulates an Early-Response Gene Containing Homology to Platelet Proteins,”Nature, 315:672-676 (1985).
Farber, J.M., “A Macrophage mRNA Selectively Induced by γ-Interferon Encodes a Member of the Platelet Factor 4 Family of Cytokines,”Proc. Natl. Acad. Sci. USA, 87:5238-5242 (1990).
Farber, J.M., “HuMIG: A New Human Member of the Chemokine Family of Cytokines,”Biochem. Biophys. Res. Commun., 192:(1):223-230 (1993).
Liao, F., et al., “Human Mig Chemokine: Biochemical and Functional Characterization,”J. Exp. Med.182:1301-1314 (1995).
Förster, R., et al., “A General Method for Screening mAbs Specific for G-protein Coupled Receptors as Exemplified by Using Epitope Tagged BLR1-Transfected 293 Cells and Solid-Phase Cell ELISA,”Biochem. Biophys. Res. Commun., 196(3):1496-1503 (1993).
Loetscher, M., et al., “Chemokine Receptor Specific for IP10 and Mig: Strcuture, Function, and Expression in Activated T-Lymphocytes,”J. Exp. Med., 184:963-969 (1996).
Miller, M.D. and Krangel, M.S., “Biology and Biochemistry of the Chemokines: A Family of Chemotactic and Inflammatory Cytokines,”Critical Reviews in Immunology, 12 (1,2):17-46 (1992).
Gayle III, R.B., et al., “Importance of the Amino Terminus of the Interleukin-8 Receptor in Ligand Interactions,”J. Biol. Chem., 268(10):7283-7289 (1993).
Sprenger, H., et al., “Structure, Genomic Organization, and Expression of the Human Interleukin-8 Receptor B Gene,”J. Biol. Chem., 269(15):11065-11072 (1994).
Oliveira, L., et al., “A Common Motif in G-Protein-Coupled Seven Transmembrane Helix Receptors,”J. Computer-Aided Molecular Design, 7:649-658 (1993).
Dewald, B., et al., “IP-10, a γ-interferon-inducible Protein Related to Interleukin-8, Lacks Neutrophil Activating Properties,”Immunol. Let., 32:81-84 (1992).
Chuntharapai, A. and Kim, K.J., “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Kaplan, G., et al., “The Expression of γ Interferon-induced Protein (IP-10) in Delayed Immune Responses in Human Skin,”J. Exp. Med., 166:1098-1108 (1987).
Gottlieb, A.B., et al., “Detection of a γ Interferon-induced Protein IP-10 in Psoriatic Plaques,”J. Exp. Med., 168:941-948 (1988).
George, D.G., et al., “Current Methods in Sequence Comparison and Analysis,”Macromolecular Sequencing and Synthesis Selected Methods and Applications, (Alan R. Liss, Inc.) pp. 127-149 (1988).
Cunningham, B.C., and Wells, J.A., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science, 244:1081-1085 (1989).
Belperio, John A., et al., “Critical Role for CXCR3 Chemokine Biology in the Pathogenesis of Bronchiolitis Obliterans Syndrome,”The Journal of Immunology, 169:1037-1049 (2002).
Brown, K.A., “Factors Modifying the Migration of Lymphocytes Across the Blood-Brain Barrier,”International Immunopharmacology, 1:2043-2062 (2001).
Kawai et al., “Intrathecal Adminstration of Antibodies Against LFA-1 and Against ICAM-1 Suppresses Experimental Allergic Encephalomyelitis in Rats,”Cell. Immunol., 171(2):262-268 (1996).
Lu, B., et al., “Structure and Function of the Murine Chemokine Receptor CXCR3,”Eur. J. Immunol., 29:3804-3812 (1999).
Soto, H., et al., “The CC Chemokine 6Ckine Binds the CXC Chemokine Receptor CXCR3,”Proc. Natl. Acad. Sci. USA, 95:8205-8210 (1998).
Holst, B., et al., “Steric Hindrance Mutagenesis Versus Alanine Scan in Mapping of Ligand Binding Sites in the Tachykinin NK1Receptor,”Mol. Pharmacol., 53:166-175 (1998).
Ausubel, F.M., et al., “Hybridization Analysis of DNA Blots,” InCurrent Protocols In Molecular Biology, John Wiley & Sons, Inc., (New York, NY), pp. 2.10.1-2.10.16 (1993).
Murphy, P.M. and Tiffany, H.L., “Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor,”Science, 253:1280-1283 (1991).
Gerard, C. and Gerard, N.P., “The Pro-Inflammatory Seven-Transmembrane Segment Receptors of the Leukocyte,”Curr. Opin. Immunol., 6:140-145 (1994).
Higgins, D.G. and Sharp, P.M., “CLUSTAL: A Package for Performing Multiple Sequence Alignment on a Microcomputer,”Gene, 73:237-244 (1988).
Qin, S., et al., “The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions,”J. Clin. Invest., 101:746-754 (1998).
Mikayama, T., et al., “Molecular Cloning and Functional Expression of a cDNA Encoding
Loetscher Marcel
Mackay Charles R.
Moser Bernhard
Qin Shixin
Hamilton, Brook, Smith and Reynolds, P.C.
Millennium Pharmaceuticals Inc.
Pak Michael
Theodor-Kocher Institute
LandOfFree
Method of inhibiting leukocytes with human CXC chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting leukocytes with human CXC chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting leukocytes with human CXC chemokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015282